Skip to main content

H.R. 2815

Referred to Committee

BIOSIM Act

Introduced 4/22/2021•117th Congress•House

Latest Action

Referred to the Subcommittee on Health.

4/23/2021 • House

Summary

Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act

This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.

Introduced in House • 4/22/2021

Enter your district to see how this bill affects your community
-

Topics & Subjects

Policy Area: Health
Health care costs and insuranceMedicarePrescription drugsProduct development and innovation

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (5)

Party Breakdown

4
Democrats
1
Republicans
0
Independents

Sponsor

R[
Rep. Schrader, Kurt [D-OR-5]

Democrat • OR-5

Sponsored 4/22/2021

Cosponsors (4)

R[
Rep. Kinzinger, Adam [R-IL-16]

R-IL-16

Joined 4/22/2021

R[
Rep. Sherrill, Mikie [D-NJ-11]

D-NJ-11

Joined 6/29/2021

R[
Rep. Butterfield, G. K. [D-NC-1]

D-NC-1

Joined 6/29/2021

R[
Rep. Schrier, Kim [D-WA-8]

D-WA-8

Joined 7/22/2021

Bill Journey

Originated in the House

Introduced

April 22, 2021

Referred to the Subcommittee on Social Security.

Committee Review

Floor Debate

Passed Chamber

Other Chamber

President

Enacted into Law

Text Versions (1)

Introduced in House4/22/2021

Details

Bill TypeHR
Current StatusReferred to Committee
Cosponsors4